Target EGFR therapeutic monoclonal antibodies, namely cetuximab, panitumumab and some small tyrosine kinase inhibitors (TKIs), have gotten approval in treating colorectal cancer [47]. This evidence concerns the gene EGFR and colorectal cancer.